S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:NLTX

Neoleukin Therapeutics (NLTX) Stock Price, News & Analysis

$50.90
+1.64 (+3.33%)
(As of 03/28/2024 ET)
Today's Range
$46.69
$52.50
50-Day Range
$29.14
$49.88
52-Week Range
$2.03
$14.36
Volume
346,901 shs
Average Volume
50,104 shs
Market Capitalization
$478.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
NLTX stock logo

About Neoleukin Therapeutics Stock (NASDAQ:NLTX)

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

NLTX Stock Price History

NLTX Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity
Did you make $29,000 two days with AI options trades?
What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:
Neurogene, Neoleukin Announce Planned Merger
See More Headlines
Receive NLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NLTX
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.00
High Stock Price Target
$30.00
Low Stock Price Target
$30.00
Potential Upside/Downside
-41.1%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-57,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.08 per share

Miscellaneous

Free Float
9,250,000
Market Cap
$478.36 million
Optionable
Optionable
Beta
1.11
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

NLTX Stock Analysis - Frequently Asked Questions

What is Neoleukin Therapeutics' stock price target for 2024?

0 Wall Street research analysts have issued 12 month target prices for Neoleukin Therapeutics' stock. Their NLTX share price targets range from $30.00 to $30.00. On average, they predict the company's share price to reach $30.00 in the next twelve months. This suggests that the stock has a possible downside of 41.1%.
View analysts price targets for NLTX
or view top-rated stocks among Wall Street analysts.

How have NLTX shares performed in 2024?

Neoleukin Therapeutics' stock was trading at $19.38 at the start of the year. Since then, NLTX shares have increased by 162.6% and is now trading at $50.90.
View the best growth stocks for 2024 here
.

How were Neoleukin Therapeutics' earnings last quarter?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) issued its earnings results on Thursday, November, 4th. The company reported ($5.60) EPS for the quarter, meeting analysts' consensus estimates of ($5.60).

When did Neoleukin Therapeutics' stock split?

Shares of Neoleukin Therapeutics reverse split before market open on Tuesday, December 19th 2023. The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Neoleukin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), RTX (RTX), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD).

Who are Neoleukin Therapeutics' major shareholders?

Neoleukin Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Carl Walkey, Jonathan G Drachman, Priti Patel and Sean Michael Smith.
View institutional ownership trends
.

How do I buy shares of Neoleukin Therapeutics?

Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NLTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners